← ANALYST RATINGS · TIPRANKS
NeuroPace (NPCE): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $20.67, the highest $22.00, the lowest $19.00. The average is +68.8% from the last price of $12.24.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $12.50 → $12.00−4.0% | Hold | −2.0% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $12.50 → $12.00−4.0% | Hold | −2.0% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $12.50 → $12.00−4.0% | Hold | −2.0% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $12.50 → $12.00−4.0% | Hold | −2.0% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $13.00 → $12.50−3.8% | Hold | +2.1% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $13.00 → $12.50−3.8% | Hold | +2.1% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| Brett Fishbin★★★★★★★★★★#10514 · hits 45% · avg −3.0% | KeyBanc | $18.00 | Buy | +47.1% | Initiated | 17.09.26on TipRanks 19:35 | +0.8%next day +0.3% · 5 days −2.8% | ↗ |
| Sarah James★★★★★★★★★★#2265 · hits 55% · avg +5.7% | Cantor Fitzgerald | $21.00 | Buy | +71.6% | Reiterated | 17.08.26on TipRanks 08:35 | −2.8%next day +2.0% · 5 days −0.8% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $20.00 | Buy | +63.4% | Reiterated | 13.08.26on TipRanks 06:45 | −1.0%next day +2.0% · 5 days −1.4% | ↗ |
| Unknown Analyst | J.P. Morgan | $20.00 | Buy | +63.4% | Reiterated | 12.08.26on TipRanks Aug 13 06:45 | −3.5%next day −1.0% · 5 days +1.0% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $19.00 | Buy | +55.2% | Assigned | 12.08.26on TipRanks 06:55 | −3.5%next day −1.0% · 5 days +1.0% | ↗ |
| Frank Takkinen★★★★★★★★★★#11823 · hits 38% · avg −3.6% | Lake Street | $20.00 | Buy | +63.4% | Reiterated | 29.07.26on TipRanks 11:12 | −9.4%next day −0.9% · 5 days −5.1% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $22.00 | Buy | +79.7% | Reiterated | 28.07.26on TipRanks Jul 29 08:20 | −0.2%next day −9.4% · 5 days −11.8% | ↗ |
| Vik Chopra★★★★★★★★★★#6076 · hits 45% · avg +1.9% | BMO Capital | $19.00 | Buy | +55.2% | Reiterated | 06.03.26on TipRanks Mar 7 04:50 | +4.5%next day −0.7% · 5 days +1.9% | ↗ |
| Priya Sachdeva★★★★★★★★★★#3757 · hits 73% · avg +21.3% | UBS | $18.00 → $22.00+22.2% | Buy | +79.7% | Reiterated | 16.12.25on TipRanks 07:55 | 0.0%next day −0.5% · 5 days +1.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering NeuroPace
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $20.00 at a price of $13.76 (+45.3%); now: $20.00 at $12.24 (+63.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 2 | 5 | 5 | 5 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.11 (from $-0.15 to $-0.05). Last quarter: $-0.18.
Sales
Next quarter’s sales estimate — $27M (from $26M to $28M). Last quarter: $23M.
Best top-analyst consensus in the sector · Healthcare
About NeuroPace
- CEO: Joel D. Becker
- Employees: 220
- 455 North Bernardo Avenue, Mountain View, CA, 94043, US
- www.neuropace.com
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Data from the stock’s TipRanks forecast page, read 97 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗